These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21840057)

  • 1. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer.
    Squires H; Tappenden P; Cooper K; Carroll C; Logan R; Hind D
    Clin Ther; 2011 Sep; 33(9):1289-305. PubMed ID: 21840057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic model of long-term use of celecoxib in patients with osteoarthritis.
    Loyd M; Rublee D; Jacobs P
    BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses.
    Pence BC; Belasco EJ; Lyford CP
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):399-405. PubMed ID: 23250933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
    Brereton N; Pennington B; Ekelund M; Akehurst R
    J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
    Hur C; Simon LS; Gazelle GS
    Cancer; 2004 Jul; 101(1):189-97. PubMed ID: 15222006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
    Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
    Arguedas MR; Heudebert GR; Wilcox CM
    Aliment Pharmacol Ther; 2001 May; 15(5):631-8. PubMed ID: 11328256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
    Brereton N; Winn B; Akehurst R
    J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preferences for the chemoprevention of colorectal cancer.
    Hur C; Broughton DE; Kong CY; Ozanne EM; Richards EB; Truong T; Gazelle GS
    Dig Dis Sci; 2009 Oct; 54(10):2207-14. PubMed ID: 19057995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.
    Ladabaum U; Chopra CL; Huang G; Scheiman JM; Chernew ME; Fendrick AM
    Ann Intern Med; 2001 Nov; 135(9):769-81. PubMed ID: 11694102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib for the prevention of sporadic colorectal adenomas.
    Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
    N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
    Gill S; Sinicrope FA
    Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?
    Biltaji E; Walker B; Au TH; Rivers Z; Ose J; Li CI; Brixner DI; Stenehjem DD; Ulrich CM
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1106-1113. PubMed ID: 33849967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis.
    DuPont AW; Arguedas MR; Wilcox CM
    Aliment Pharmacol Ther; 2007 Aug; 26(3):431-41. PubMed ID: 17635378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.